• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3: New insider Ecor1 Capital, Llc claimed ownership of 5,701,669 shares

    11/18/21 1:00:36 PM ET
    $ODT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ODT alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    EcoR1 Capital, LLC

    (Last) (First) (Middle)
    357 TEHAMA STREET #3

    (Street)
    SAN FRANCISCO CA 94103

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    11/17/2021
    3. Issuer Name and Ticker or Trading Symbol
    Odonate Therapeutics, Inc. [ ODT ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 5,701,669(2) I See Note 1(1)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 3 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein.
    2. Qualified Fund directly holds 4,999,757 of the shares of Common Stock reported in this Form 3.
    Oleg Nodelman, Manager of EcoR1 Capital, LLC 11/18/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ODT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ODT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ODT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Odonate Announces Expected Delisting of Its Stock

      Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced that on January 6, 2022 it received written notice from The Nasdaq Stock Market LLC ("Nasdaq") notifying Odonate that Nasdaq believes that Odonate is a "public shell" pursuant to Listing Rule 5101, and that the continued listing of its securities is no longer warranted. Odonate will not appeal this determination. Therefore, Odonate expects the trading of its common stock on The Nasdaq Stock Market to be suspended at the opening of business on January 18, 2022, and that Nasdaq will file a Form 25-NSE with the U.S. Securities and Exchange Commission (the "SEC"), which will remove Odonate's securities from listing and registration on The

      1/7/22 9:00:00 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics Announces Planned Return of Capital to Stockholders through Share Repurchase Plan

      Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced that it will commence a share repurchase plan for up to 20 million shares in order to return capital to stockholders. This action is in connection with the Company's previously announced decision to discontinue the development of tesetaxel. Repurchases may be made from time to time at the Company's discretion. The plan has no time limit and can be discontinued at any time. There can be no assurance as to the timing or number of shares of any repurchases. As of September 30, 2021, as reported in its recently filed Form 10-Q, the Company had total stockholders' equity of $71.4 million, or $1.85 per share, based on 38.5 million shares ou

      11/17/21 7:45:00 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021

      Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced financial results for the three and nine months ended September 30, 2021. As of September 30, 2021, Odonate had $95.0 million in cash compared to $157.3 million as of December 31, 2020. Odonate's cash used in operating activities for the three and nine months ended September 30, 2021 was $15.1 million and $63.0 million, respectively. Odonate's net loss for the three and nine months ended September 30, 2021 was $14.0 million and $69.8 million, or $0.37 and $1.85 per share, respectively, compared to $30.5 million and $94.1 million, or $0.93 and $3.00 per share, respectively, for the same periods in 2020. About Odonate Therapeutics, In

      11/10/21 5:15:00 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ODT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Odonate Therapeutics downgraded by Jefferies with a new price target

      Jefferies downgraded Odonate Therapeutics from Buy to Hold and set a new price target of $4.00 from $45.00 previously

      3/22/21 12:46:40 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics downgraded by Cowen

      Cowen downgraded Odonate Therapeutics from Outperform to Market Perform

      3/22/21 11:27:45 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ODT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Ecor1 Capital, Llc bought $308,662 worth of shares (185,941 units at $1.66) and sold $9,741,063 worth of shares (5,887,610 units at $1.65)

      4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)

      12/10/21 6:50:07 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Boxer Capital, Llc sold $623,340 worth of shares (400,000 units at $1.56)

      4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)

      11/24/21 6:00:33 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Davis Aaron I. sold $2,499,948 worth of shares (1,200,000 units at $2.08)

      4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)

      11/19/21 7:22:38 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ODT
    SEC Filings

    See more
    • SEC Form 25-NSE filed by Odonate Therapeutics Inc.

      25-NSE - Odonate Therapeutics, Inc. (0001717452) (Subject)

      1/25/22 5:30:50 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics, Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - Odonate Therapeutics, Inc. (0001717452) (Filer)

      1/7/22 9:00:35 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics, Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Odonate Therapeutics, Inc. (0001717452) (Filer)

      11/18/21 5:00:34 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ODT
    Financials

    Live finance-specific insights

    See more
    • Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021

      Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced financial results for the three and nine months ended September 30, 2021. As of September 30, 2021, Odonate had $95.0 million in cash compared to $157.3 million as of December 31, 2020. Odonate's cash used in operating activities for the three and nine months ended September 30, 2021 was $15.1 million and $63.0 million, respectively. Odonate's net loss for the three and nine months ended September 30, 2021 was $14.0 million and $69.8 million, or $0.37 and $1.85 per share, respectively, compared to $30.5 million and $94.1 million, or $0.93 and $3.00 per share, respectively, for the same periods in 2020. About Odonate Therapeutics, In

      11/10/21 5:15:00 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021

      Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced financial results for the three and six months ended June 30, 2021. In March 2021, Odonate announced the discontinuation of development of tesetaxel and its intent to wind down tesetaxel-related operations. As of June 30, 2021, Odonate has transitioned all patients in tesetaxel studies to appropriate alternative therapies or facilitated continuation of treatment with tesetaxel under compassionate use programs where appropriate. As of June 30, 2021, Odonate had $110.1 million in cash compared to $157.3 million as of December 31, 2020. This decrease in cash resulted primarily from cash used in operating activities for the six months en

      7/27/21 8:30:00 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics Announces Financial Results for the Three Months Ended March 31, 2021

      Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced financial results for the three months ended March 31, 2021. Odonate recently announced the discontinuation of development of tesetaxel and its intent to wind down tesetaxel-related operations. Odonate is working with clinical sites to transition patients in ongoing tesetaxel studies to appropriate alternative therapies or facilitate continuation of treatment with tesetaxel under compassionate use programs where appropriate. As of March 31, 2021, Odonate had $133.2 million in cash compared to $157.3 million as of December 31, 2020. This decrease in cash resulted primarily from cash used in operating activities for the three months en

      5/14/21 8:30:00 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ODT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Odonate Therapeutics, Inc. (Amendment)

      SC 13G/A - Odonate Therapeutics, Inc. (0001717452) (Subject)

      12/10/21 5:24:12 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Odonate Therapeutics, Inc. (Amendment)

      SC 13D/A - Odonate Therapeutics, Inc. (0001717452) (Subject)

      11/26/21 5:01:04 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Odonate Therapeutics, Inc. (Amendment)

      SC 13D/A - Odonate Therapeutics, Inc. (0001717452) (Subject)

      11/22/21 11:08:29 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care